1. What Is Melanotan II
Melanotan II (MT-II) is a synthetic cyclic heptapeptide developed at the University of Arizona in the early 1990s as an analog of alpha-melanocyte-stimulating hormone (α-MSH). Its sequence — Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ — incorporates a lactam bridge between the aspartic acid and lysine side chains, creating a cyclic structure that increases receptor binding affinity and metabolic stability compared to the native linear hormone.
Melanotan II is one of the most widely circulated compounds in the gray-market research peptide space. It is primarily used for its tanning (skin-darkening) effects, though it also affects appetite and sexual function through its activity at multiple melanocortin receptor subtypes. It has never been approved for medical use in any jurisdiction.
Two FDA-approved drugs are derived from the same melanocortin research lineage: afamelanotide (Scenesse®, a linear α-MSH analog approved for erythropoietic protoporphyria) and bremelanotide (Vyleesi®, a metabolite of Melanotan II approved for hypoactive sexual desire disorder in premenopausal women). Melanotan II itself is distinct from both and carries a different risk profile due to its non-selective receptor activity and unregulated manufacturing.
2. Mechanism of Action
Melanotan II is a non-selective agonist of melanocortin receptors. Unlike afamelanotide (which primarily targets MC1R) or bremelanotide (which primarily targets MC4R), Melanotan II activates multiple receptor subtypes, producing a broader range of physiological effects.
MC1R — Skin Pigmentation
Activation of MC1R on melanocytes stimulates melanin production (melanogenesis), leading to skin darkening independent of UV exposure. This is the primary effect most users seek. MC1R-driven melanogenesis produces eumelanin, the darker form of melanin associated with photoprotection.
MC3R and MC4R — Appetite and Sexual Function
MC4R activation in the central nervous system mediates appetite suppression and sexual arousal. MC3R is also involved in energy homeostasis. The sexual effects observed with Melanotan II — including penile erections in males — led to the development of bremelanotide (PT-141), which was specifically optimized for MC4R activity and subsequently gained FDA approval.
MC5R — Exocrine Function
MC5R is expressed in exocrine glands and is involved in sebaceous gland secretion. The clinical significance of MC5R activation by Melanotan II is not well characterized, but it contributes to the compound's non-selective activity profile.
The non-selective nature of Melanotan II's receptor binding is a key distinction from its approved derivatives. Activating multiple melanocortin receptors simultaneously produces a wider range of effects — and a wider range of potential side effects — than receptor-selective compounds.
3. Clinical Evidence
The clinical evidence base for Melanotan II is extremely thin. Formal pharmaceutical development was abandoned, and the compound has primarily been studied through case reports and surveillance data rather than controlled trials.
Regulatory Status
- Not FDA-approved for any indication. The FDA has issued warning letters regarding injectable tanning products containing Melanotan II.
- Banned or warned against in multiple countries. Australia's TGA has warned consumers to avoid Melanotan II, stating that development was halted for safety reasons. Health agencies in several other countries have issued similar warnings since 2007.
- The Skin Cancer Foundation has issued a public warning advising against injectable and intranasal tanning products, citing unknown short- and long-term effects and documented reports of mole changes and melanoma.
- Not the same as approved drugs. Melanotan II should not be confused with afamelanotide (Scenesse®) or bremelanotide (Vyleesi®), which underwent full regulatory review and are distinct compounds with different safety profiles.
4. What to Look for in a COA
When evaluating a Certificate of Analysis for a Melanotan II product, confirm the following:
Identity confirmation via mass spectrometry — the molecular ion should appear at m/z 1025.2 [M+H]+ or m/z 513.1 [M+2H]2+ (the doubly charged ion commonly used in LC-MS/MS analysis)
HPLC purity of 98% or higher from a named, independent third-party lab
Amino acid analysis or sequence confirmation verifying the correct cyclic structure, including the D-Phe residue and the Asp-Lys lactam bridge
Endotoxin and sterility testing for any injectable preparation
Peptide content (net peptide content after accounting for water, salts, and counterions) — reference standards range from 69–88% peptide content, so the labeled mass of lyophilized powder is not equivalent to active peptide mass
A batch or lot number matching the product received
A verifiable lab reference number from an independent, named testing laboratory
Test date — as with any peptide, a COA from months or years ago may not reflect current product purity
Red flags on a Melanotan II COA: missing mass spectrometry data (HPLC alone cannot confirm the correct sequence or cyclic structure), purity below 95%, absence of endotoxin results on injectable products, or a claimed vial content that seems inconsistent with purity and peptide content data.
For a full walkthrough of evaluating a COA, see our guide to reading a peptide COA.
5. Testing Considerations
Melanotan II presents specific quality and analytical challenges due to its cyclic structure, its prevalence on the unregulated market, and documented content variability across suppliers.
Analytical Methods
The established analytical approach for Melanotan II uses reversed-phase HPLC with UV detection at 218 nm for purity determination, combined with LC-MS/MS using electrospray ionization for identity confirmation. The doubly charged precursor ion at m/z 513.1 [M+2H]²⁺is typically monitored in MRM (multiple reaction monitoring) mode. Published validation data shows accuracy of 99–101% and precision below 2% RSD for this methodology.
Documented Content Variability
A peer-reviewed 2014 study (Breindahl et al.) analyzed 26 vials of Melanotan II purchased from three online suppliers. All vials were labeled as containing 10 mg. Actual measured content ranged from 4.32 to 8.84 mg per vial — meaning products contained as little as 43% of the labeled amount. Two of three suppliers had unknown impurities totaling 4–6% by HPLC area. This study remains one of the only independent laboratory analyses of gray-market Melanotan II products.
Stability and Storage
As a lyophilized powder, Melanotan II is reported to be stable for approximately 3 years when stored at -20°C. In solution, stability drops — solutions should be stored at -80°C (up to 1 year) or -20°C (up to 1 month), and repeated freeze-thaw cycles should be avoided. Laboratory testing has shown aqueous solutions remain stable for at least 48 hours under refrigerated (4°C) and frozen (-22°C) conditions, with less than 2.1% change in response.
Substitution and Misidentification Risks
Melanotan II is a cyclic peptide with a specific lactam bridge. The related linear peptide afamelanotide (Melanotan I) has a different structure and receptor selectivity profile. Mass spectrometry is essential to distinguish Melanotan II from linear fragments, synthesis by-products, or different melanocortin analogs. HPLC purity alone cannot confirm the cyclic structure or the presence of the D-phenylalanine residue, both of which are critical to the compound's activity.
Net Peptide Content
Melanotan II is typically supplied as an acetate salt (MW 1084.22 Da as acetate vs. 1024.18 Da free base). Commercial reference standards show peptide content ranging from 69% to 88% by nitrogen analysis — the remainder is water, counterions, and residual salts. This means the mass of lyophilized powder in a vial is not equivalent to the mass of active peptide. A properly detailed COA should report both gross weight and net peptide content.
Summary
Melanotan II is a synthetic cyclic peptide that acts as a non-selective melanocortin receptor agonist. It is not approved for medical use in any country, and health agencies including the FDA, TGA, and the Skin Cancer Foundation have issued public warnings against its use. Clinical data is limited to a single uncontrolled pilot study and case reports. Independent laboratory testing has documented significant content variability and impurities in gray-market products.
When evaluating a Melanotan II product, prioritize third-party lab testing showing HPLC purity at or above 98%, mass spectrometric identity confirmation at m/z 1025.2 [M+H]+ or 513.1 [M+2H]²⁺, and — for any injectable preparation — verified endotoxin and sterility testing from an independent laboratory.